1Beta - Blocker Evaluation of Survival Trial Investigators. A trial of the beta - blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med, 2001,344:1659- 1667.
2Bristow MR. Adrenergie receptor blockade in chronic heart failure. Circulation, 2000, 101:558 - 569.
3Heart Failure Society d America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction -pharmacological approaches. Pharmacotherapy, 2000, 20:495 - 522.
4Pitt B, Zannad F, Remme WJ, et al. The effect d spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999, 341(10) :709 - 717.
5Cicoira M, ZanoUa L, Roesi A, et al. Long- term, dose - dependent effects of spironolactone on left ventricular function and exercise telerance in patients with chronic heart failure. J Am Coll Cardiol, 2002,40(2) :304 - 310.
6Pitt B, Poole - Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Lossrtan Heart Failure Survival Study ELITE Ⅱ. Lancet, 2000,355(9215) :1582 - 1587.
7Cohn JN, Tognoni G. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345(23) :1667 - 75.
8The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Meal, 1997,336(8) :525 - 33.
9Cohn JN, Archibald DG, Zieeche S, etal. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med, 1986,314(24):1547 - 1552.
10Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine - isosorbide dinitiate in the treatment of chronic congestive heart failure. N Engl J Med, 1991,325(5):303 - 310.
